Veracyte Closes $150M Acquisition of Convergent Genomics, Bolstering UroAmp Bladder Cancer Platform
VCYT sits 40% above its 52-week low of $29.455.
Summary
Veracyte completed its $150M acquisition of Convergent Genomics, adding the UroAmp urinary tumor DNA platform for bladder cancer monitoring. Up to $30M in additional milestone payments are tied to reimbursement achievements.
Key Events · M&A and Partnerships · VCYT
-
Acquisition Completed
On September 14, 2026, the acquisition of Convergent Genomics closed, bringing the UroAmp urinary tumor DNA platform into Veracyte's urology diagnostics portfolio.
-
Deal Terms
The deal includes $150 million in upfront cash, up to $30 million in additional cash tied to UroAmp reimbursement milestones, a $15M indemnity escrow, and a $1M adjustment escrow.
-
Strategic Rationale
UroAmp complements Veracyte's existing Decipher Bladder and TrueMRD tests, enabling genomic insights from urine, tissue, and blood across the bladder cancer care continuum.
-
Commercial Timeline
The first test is expected to commercialize in late 2028, subject to reimbursement timelines, with an initial indication targeting BCG induction therapy response monitoring.
Analysis · VCYT · Industrial Applications And Services
The acquisition of Convergent Genomics closed for $150 million upfront, with up to $30 million more in milestone payments. UroAmp, a urinary tumor DNA testing platform for bladder cancer, now joins Veracyte's urology portfolio. This move strategically expands into non-muscle invasive bladder cancer monitoring, complementing the existing Decipher Bladder and TrueMRD tests. The cash-funded deal is financially manageable, as Veracyte confirmed no update is needed to its 2026 adjusted EBITDA guidance. The first commercial test is expected in late 2028, subject to reimbursement timelines.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1179 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VCYT was trading at $41.21 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $29.46 to $60.91. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.